Non-coding genetic variation at TCF7L2 is the strongest genetic determinant of type 2 diabetes (T2D) risk in humans. TCF7L2 encodes a transcription factor mediating the nuclear effects of WNT signalling in adipose tissue (AT). Here we mapped the expression of TCF7L2 in human AT and investigated its role in adipose progenitor (AP) biology. APs exhibited the highest TCF7L2 mRNA abundance compared to mature adipocytes and adipose-derived endothelial cells. Obesity was associated with reduced TCF7L2 transcript levels in subcutaneous abdominal AT but increased expression in APs. In functional studies, TCF7L2 knockdown (KD) in APs led to dose-dependent activation of WNT/β-catenin signaling, impaired proliferation and dose-dependent effects on adipogenesis. Whilst partial KD enhanced adipocyte differentiation, complete KD impaired lipid accumulation and adipogenic gene expression. Overexpression of TCF7L2 accelerated adipogenesis.
INTRODUCTION 1
Adipose tissue (AT) plays a central role in the regulation of whole-body energy and glucose 2 homoeostasis. Firstly, it provides a safe depot for the storage of excess calories in the form of 3 triglycerides, thereby protecting extra-adipose tissues from lipotoxicity (1). Secondly, it releases 4 energy as free fatty acids during periods of energy demand such as fasting and exercise. Finally, 5 through the secretion of peptide hormones such as leptin and adiponectin it directly regulates systemic 6 energy balance and insulin sensitivity (2). AT expands through an increase in adipocyte number 7 (hyperplasia) and/or size (hypertrophy). Hyperplastic AT growth is mediated via generation of new 8 adipocytes from adipose progenitors (APs) and is associated with enhanced systemic insulin 9 sensitivity and an improved glucose and lipid profile. In contrast, adipocyte hypertrophy results in 10 AT inflammation and fibrosis which lead to the development of insulin resistance (3, 4) . 11 12 WNTs are a family of secreted growth factors which function in autocrine and paracrine fashions to 13 regulate stem cell and AP biology (5-7). WNTs signal through frizzled (FZD) receptors to activate 14 multiple downstream signalling cascades. In the best characterized, canonical pathway, WNT binding 15
to FZDs leads to nuclear accumulation of the transcriptional co-activator β-catenin which in 16 conjunction with TCF/LEF transcription factors activates WNT target gene expression. In the absence 17 of WNTs, TCF/LEF proteins are bound to members of the Groucho/TLE family of transcriptional 18 co-repressors and suppress WNT/β-catenin signalling. There are four TCF/LEF family members in 19 mammals; TCF7, TCF7L1, TCF7L2 and LEF1 (8). Of these, TCF7L2 is the most highly expressed 20 in AT (9). 21 22 Work from the MacDougald laboratory first highlighted a potential role for TCF7L2 in the regulation 23 of AT function (10). A dominant negative TCF7L2 mutant lacking its β-catenin binding domain was 24 shown to cause spontaneous adipogenesis of 3T3-L1 cells and trans-differentiation of C2C12 25 myoblasts into adipocytes. More recently, the in vitro role of TCF7L2 in the regulation of 26 adipogenesis was revisited with conflicting results. Whilst Chen et al showed that TCF7L2 27 knockdown (KD) in 3T3-L1 preadipocytes leads to impaired adipocyte differentiation (11) in another 28 study inducible TCF7L2 deletion in immortalised inguinal mouse APs was associated with enhanced 29 adipogenesis (12). Ex vivo adipose expression of Tcf7l2 was suppressed by high-fat diet (HFD)-30 induced and genetic obesity (12, 13) . In vivo, homozygous global Tcf7l2 null mice die perinatally 31 whereas heterozygous null animals are lean with enhanced glucose tolerance and insulin sensitivity 32 compared to wild-type controls both on a chow and following a HFD (14). Conversely, transgenic 33 mice over-expressing Tcf7l2 displayed HFD-induced glucose intolerance (14) . Contrasting these 34 findings, targeted deletion of Tcf7l2 in mature adipocytes (mADs) resulted in enhanced adiposity, 35 glucose intolerance and hyperinsulinaemia (11, 12) . In humans, TCF7L2 expression was decreased in 36 the SC abdominal (hereafter referred to as abdominal) AT of subjects with impaired glucose tolerance 37 (11) and reduced systemic insulin sensitivity (15) . Notably, non-coding genetic variation at the 38 TCF7L2 locus was demonstrated to be the strongest genetic determinant of type 2 diabetes (T2D) risk 39 in humans (16, 17) . The same single nucleotide variation (SNV), rs7903146, was also associated with 40 fat distribution (18). Prompted by these findings we investigated the role of TCF7L2 in human AT 41 function. 42
43

RESEARCH DESIGN AND METHODS 44
Study population: Study subjects were recruited from the Oxford Biobank 45 (www.oxfordbiobank.org.uk), a population-based cohort of healthy 30-50-year-old volunteers (19) . 46
Paired abdominal and visceral biopsies were collected from patients undergoing elective surgery as 47 a part of the MolSURG study. Plasma biochemistry (19) and adipocyte sizing (20) were undertaken 48 as described. All studies were approved by the Oxfordshire Clinical Research Ethics Committee, and 49 all volunteers gave written, informed consent. 50 transcript levels were similar in the abdominal and visceral AT depots ( Fig. 1B) . In fractionated AT 113 from over 100 healthy volunteers, TCF7L2 mRNA levels were higher in APs compared with mADs 114 from both the abdominal and gluteal fat depots (Fig. 1C ). Furthermore, in a small sample group (n=5-115 6), TCF7L2 expression was higher in APs versus adipose-derived endothelial cells ( Fig. 1D ). Finally, 116 TCF7L2 mRNA abundance in abdominal APs correlated positively with body mass index (BMI) 117 whilst an opposite trend was detected in abdominal mADs (Fig. 1E, F) . No associations between BMI 118 and TCF7L2 expression in gluteal adipose cell fractions were detected ( Fig. S1 ). Based on these data 119 we focused our subsequent studies on deciphering the function of TCF7L2 in APs. 120 121 TCF7L2 dose-dependently modulates AP differentiation. We investigated the role of TCF7L2 in 122 AP biology using de-differentiated fat (DFAT) cells generated from immortalised abdominal 123 adipocytes (22). These retain their depot-specific gene expression signature ( Fig. S2 ) and have a 124 higher adipogenic capacity than primary and immortalised APs. Stable KD of TCF7L2 in these cells 125 was achieved with two shRNAs targeting the universal exon 9 of TCF7L2 ( Fig. 2A, B ). The first 126 shRNA (sh897) led to 30% KD of TCF7L2 at mRNA level and 68% KD at protein level. The second, 127 more efficient shRNA (sh843), led to 70% reduction in TCF7L2 expression and near complete 128 TCF7L2 protein KD. KD of TCF7L2 led to impaired AP proliferation ( Fig. 2C ). No differences in 129 the doubling time of moderate-versus high-efficiency TCF7L2-KD cells were detected. Partial 130 TCF7L2-KD was also associated with augmented adipocyte differentiation as ascertained by 131 increased lipid accumulation and enhanced adipogenic gene expression ( Fig. 2D -H) . In sharp 132 contrast, high-efficiency KD of TCF7L2 resulted in impaired adipogenesis. These findings were 133 confirmed in primary abdominal TCF7L2-KD cells from two subjects. In these latter experiments the 134 anti-adipogenic effect of sh843 was more subtle despite identical TCF7L2-KD efficiency in primary 135 and DFAT cells ( Fig. 2I, J) . In complimentary experiments we also investigated the effects of 136 inducible TCF7L2 over-expression on AP functional characteristics using a Tet-On system (Fig. 3) . 137
The doxycycline (DOX) dose was selected to induce approximately 2-and 5-fold induction in 138 TCF7L2 expression compared to vehicle treated TCF7L2 overexpressing APs which corresponded to 139 an equivalent increase in protein production (and 2.6 and 6.6-fold higher protein production versus 140 vehicle treated empty vector controls) ( Fig. 3A, B ). AP cells were grown in DOX-free media and 141 TCF7L2 expression was induced upon plating for proliferation and differentiation experiments and 142 throughout thereafter. Ectopic expression of TCF7L2 did not influence AP proliferation ( Fig. 3C ). 143
Low-dose TCF7L2 overexpression similarly did not affect adipocyte differentiation ( Fig. S3 ) 144 although, the DOX-induced increase in TCF7L2 expression was not sustained throughout 145 adipogenesis ( Fig. S4 ). On the other hand, 5-fold increase in TCF7L2 protein production accelerated 146 adipocyte differentiation ( Fig. S5 ). By the end of the differentiation time course however, TCF7L2 147 over-expressing adipocytes displayed only a subtle increase in lipid accumulation concomitant with 148 increased CEBPA expression versus vehicle treated controls ( Fig. 3D-H ). We conclude that, in vitro 149 TCF7L2 has dose-dependent actions on adipogenesis. 150 151 TCF7L2 dose-dependently modulates WNT/β-catenin signalling. We next determined whether the 152 effects of TCF7L2 on AP function were driven by changes in WNT/β-catenin signalling (Fig. 4) . 153
Partial KD of TCF7L2 did not result in altered expression of the universal WNT target gene AXIN2 154 ( Fig. 4A ). In contrast, (near) complete TCF7L2-KD was associated with increased AXIN2 levels. 155
Using TCF7L2-KD cells stably expressing the TOPflash promoter reporter construct which monitors 156 endogenous β-catenin transcriptional activity we confirmed that complete depletion of TCF7L2 was 157 associated with robust stimulation of canonical WNT signalling whilst weak activation was also seen 158 following partial KD both in the absence and presence of WNT3A ( Fig. 4B ). Interestingly, despite 159 increased β-catenin transcriptional activity, active β-catenin protein levels were decreased in both 160 sh897 and sh843 cells ( Fig. 4C ). Given the paradoxical activation of WNT/β-catenin signalling in 161 TCF7L2-KD APs we examined the expression of other TCF/LEF family members in these cells ( TCF7L2 production did not influence AP AXIN2 mRNA levels ( Fig. 4E ). In TOPflash promoter 166 assays, TCF7L2 over-expression led to inhibition of WNT/β-catenin signalling (Fig. 4F, G) . 167
However, DOX treatment also suppressed TOPflash activity in empty vector control cells. Over-168 expression of TCF7L2 did not influence active β-catenin protein levels ( Fig. 4I ). Collectively these 169 findings suggest that TCF7L2 functions to antagonize the transcriptional activity of β-catenin in 170 abdominal APs. 171 172 Transcriptome-wide profiling reveals that TCF7L2 regulates multiple aspects of AP biology. To 173 identify the genes and biological processes regulated by TCF7L2 in APs we undertook transcriptomic 174 analyses of TCF7L2-KD cells using RNA-Seq ( Fig. 5A ). High-efficiency TCF7L2-KD altered the 175 expression of 2,806 genes (18% of all expressed genes) whilst partial KD resulted in a more modest 176 change in the transcriptome with 1,024 genes differentially regulated (FDR < 5%, absolute fold-177 change > 1.5) ( Fig. 5B ). Gene set enrichment analysis revealed that the cluster of genes suppressed 178 in complete TCF7L2-KD cells was enriched for pathways and processes involved in cell cycle, 179 response to hypoxia, p53 signalling and ribosome biogenesis ( Fig. 5E ). Interestingly, cell cycle and 180 ribosome biogenesis are two key pathways that are transcriptionally positively regulated by canonical 181 WNT signalling (29). Consistent with these findings, the expression of many well-established 182 WNT/β-catenin target genes was reduced in high-efficiency TCF7L2-KD APs (Fig. S7 ). The cluster 183 of upregulated genes in high-efficiency KD cells was enriched for genes involved in interferon 184 signalling and extracellular matrix (ECM) organization. In moderate-efficiency TCF7L2-KD cells 185 the downregulated gene set was also enriched for pathways and processes involved in response to 186 hypoxia and p53 signalling ( Fig. 5F ). Additionally, we detected enrichment for circadian regulation 187 of gene expression. The upregulated gene cluster in sh897 cells was enriched for genes involved in 188 ECM organization and immune and inflammatory processes. We also performed transcription factor-189 binding site motif analysis on the promoters of genes differentially expressed in TCF7L2-KD APs 190 ( Fig. 5E , F). The promoters of genes suppressed following both complete and partial TCF7L2-KD 191 were enriched for binding sites of E2F4 and FOXM1 which regulate cell proliferation. Genes whose 192 expression was decreased in high-efficiency TCF7L2-KD cells were also enriched for TFDP1, 193 TFDP3 and KLF4 binding sites in their promoters. TFDP family members co-operatively regulate 194 cell cycle genes with members of the E2F family whilst KLF4 suppresses p53 expression and is a β-195 catenin target gene. The promoters of genes suppressed in partial TCF7L2-KD cells were also 196 enriched for HIF1A binding sites. Genes, whose expression was increased in both sh897 and sh843 197 cells, exhibited enrichment for binding sites of transcription factors involved in cytokine and 198 particularly, interferon signalling in their promoters namely, IRF1, IRF7, STAT1, and STAT2. 199
Finally, real-time PCR revealed good concordance between changes in the transcriptome of DFAT 200 and primary APs following moderate-but not after high-efficiency TCF7L2-KD ( Fig. 5G, H) . 201
202
The T2D-risk allele at rs7903146 reduces AP TCF7L2 expression. Genome wide association study 203 (GWAS) meta-analyses have revealed that non-coding genetic variation at TCF7L2 is the strongest 204 genetic determinant of T2D risk in humans (16, 17) . Previous efforts to characterize the mechanism 205 of action at TCF7L2 revealed that the fine-mapped T2D-risk allele at rs7903146 overlaps enhancer 206 histone marks in both islets and APs (30). Whilst this variant has been shown to increase TCF7L2 207 expression in islets (31), evidence demonstrating that it is associated with a cis-expression 208 quantitative trait locus (eQTL) in APs has been missing. By examining age-, BMI-and sex-adjusted 209 TCF7L2 mRNA abundance data in isolated mADs and ex vivo cultured abdominal and gluteal APs 210 from up to 21 homozygous carriers of the T2D-risk variant (T) and 59 subjects homozygous for the 211 wild-type allele (C) at rs7903146 we found that the T allele reduces TCF7L2 expression in abdominal 212 APs ( Fig. 6A, B ). A similar trend was detected in gluteal APs. We substantiated this finding in a 213 subset of samples by demonstrating lower TCF7L2 protein levels in abdominal APs derived from 214 T2D-risk variant carriers versus ancestral allele carriers ( Fig. 6C ). In cell-based luciferase assays a 215 150 base pair nucleotide genomic sequence centred around rs7903146 exhibited allele-specific 216 enhancer properties in abdominal APs and HEK293 cells with the T allele abolishing enhancer 217 activity ( Fig. 6E, F ). Histological assessment of abdominal AT biopsies from 19 age-and BMI-218 matched pairs of males homozygous either for the T2D-risk allele or the protective allele at rs7903146 219 did not reveal any difference in median adipocyte size between the two genotypes ( Fig. 6G ). 220
However, interrogation of plasma biochemistry data from 600 age-and BMI-matched pairs of 221 subjects from the Oxford Biobank showed that T2D-risk variant carriers had reduced AT insulin 222 resistance (Adipo-IR) ( Fig. 6H ) which was more pronounced in obese individuals ( Fig. 6I ). We conclude that in addition to its established role in regulating pancreatic insulin secretion, genetic 224 variation at rs7903146 may also influence T2D risk through effects on AP biology. 225
226
DISCUSSION 227
Our study highlights a complex role for TCF7L2 in AP biology and AT function. We show that 228 TCF7L2 expression is similar across different fat depots and diminishes in abdominal AT in obesity. 229
The lower AT TCF7L2 mRNA abundance in obese subjects could be mediated via increased 230 methylation at TCF7L2 (32) and may contribute to the AT dysfunction that is associated with greater 231 adiposity. Our results also revealed that TCF7L2 was highly expressed in all adipose cell lineages 232 examined, namely APs, mature adipocytes and endothelial cells with the former exhibiting the highest 233 transcript levels. These data suggest that TCF7L2 has pleiotropic roles in AT ranging from the 234 regulation of AP biology and adipogenesis, to the modulation of mature adipocyte function and 235 angiogenesis. Finally, we showed that increased adiposity was paradoxically associated with higher 236 TCF7L2 expression in isolated abdominal APs despite reduced TCF7L2 mRNA abundance in whole 237 AT. It is likely that the reduction in TCF7L2 mRNA levels in the abdominal depot in obesity is driven 238 by lower expression in adipocytes given that they are the principal cellular component of AT and as 239 hinted by the correlation data in Fig. 1F . Thus, obesity seems to lead to directionally opposite changes 240 in TCF7L2 expression in different AT cellular fractions. 241
242
To elucidate the role of TCF7L2 in AP biology, we undertook functional studies in immortalised and 243 primary APs. These revealed that TCF7L2 protein production may be regulated both transcriptionally 244 and at the level of protein translation because TCF7L2-KD was associated with more pronounced 245 changes in protein than mRNA levels. Thus in addition to regulating its own transcription (33) 246 TCF7L2 may regulate its own translation. The loss-of-function studies also showed that TCF7L2-247 KD impairs AP proliferation. Additionally, they demonstrated that TCF7L2 dose-dependently 248 regulates adipogenesis. We speculate that the primary role of TCF7L2 in APs is to restrain 249 adipogenesis since only complete TCF7L2-KD led to impaired adipocyte differentiation whilst 250 downregulation of its expression within a physiological range, in both DFAT and primary abdominal 251 APs, led to enhanced adipogenesis. 252
253
To decipher the signalling pathways mediating the actions of TCF7L2 in AP biology we examined 254 canonical WNT signalling in TCF7L2-KD cells. These experiments revealed that in abdominal APs 255 TCF7L2 may function to inhibit WNT pathway activity. Whilst prima facie paradoxical, this result 256 is in keeping with previous findings demonstrating that TCF7L2-KD in 3T3L1 cells was associated 257 with a robust increase in Axin2 expression (11). Tang et al (34) also showed that TCF7L2 displayed 258 a cell-type specific activity to both enhance and inhibit WNT signalling and localized the 259 transcriptional repressive ability of TCF7L2 to its C-terminal tail, which is present in some, so-called 260 E isoforms, but not all TCF7L2 transcript species. However, expression of E-type TCF7L2 splice 261 variants is low in AT (35,36). Additionally, none of these studies examined the expression of other 262 TCF/LEF family members in TCF7L2-KD cells (see below). WNT/β-catenin signalling is known to 263 inhibit adipogenesis. Accordingly, high-level KD of TCF7L2 was associated with impaired 264 adipogenesis concomitant with canonical WNT signalling activation. However, downregulation of 265 TCF7L2 expression within a more physiological range (using sh897) led to increased adipocyte 266 differentiation despite mild WNT/β-catenin pathway activation. These data suggest that WNT 267 signalling may have dose-dependent effects on adipogenesis and cell fate determination (21,37). 268
Additionally/alternatively TCF7L2 may engage other signalling pathways to influence AP biology. 269
270
To further elucidate the genes, pathways and biological processes regulated by TCF7L2 in APs we 271 undertook genome-wide transcriptional profiling of TCF7L2-KD cells. Consistent with our in vitro 272 studies these experiments showed that KD of TCF7L2 activates transcriptional programmes which 273 inhibit the proliferation and modulate the adipogenic capacity of APs. Furthermore, they revealed 274 that TCF7L2 can regulate many aspects of AP biology including ECM secretion, immune and 275 inflammatory signalling, and apoptosis and/or senescence. TCF7L2-KD in APs also led to 276 suppression of HIF1A signalling which promotes fibrosis and AT dysfunction (3). These findings 277 expand the potential functional repertoire of TCF7L2 in AT although, they require experimental 278 confirmation. Contrary to our expectations, the RNA-Seq experiments also revealed that TCF7L2 279 promotes canonical WNT signalling in APs. How can we reconcile this finding with our in vitro 280 studies? In TCF7L2-KD cells expression of TCF7 was upregulated. We speculate that TCF7 is a more 281 potent activator of WNT signalling in APs given that functional redundancy is common amongst 282 TCF/LEF family members (8) and based on the increased TOPflash promoter activity and AXIN2 283 expression in TCF7L2-KD cells. Nonetheless, increased TCF7 levels cannot compensate for the 284 absence of TCF7L2 at many WNT target gene promoters. Consequently, AP TCF7L2-KD leads to 285 downregulation of several classic WNT target genes and pathways. Transcription factor-binding site 286 analysis was in keeping with the results of the gene set enrichment analysis. Interestingly we saw no 287 enrichment for TCF7L2 binding in the promoters of genes suppressed in TCF7L2-KD cells. 288
However, genome-wide chromatin occupancy data have shown that TCF7L2 regulates gene 289 expression primarily by binding to intergenic regions (29,33). Lastly, the RNA-Seq data provided 290 additional evidence that partial TCF7L2-KD in DFAT cells may be more physiologically relevant as 291 we were better able to replicate changes in the transcriptome of partial versus complete TCF7L2-KD 292 DFAT cells in moderate-and high-efficiency TCF7L2-KD primary cells respectively. 293 294 GWAS meta-analyses have identified eight independent signals at TCF7L2 which are associated with 295 T2D susceptibility (17). At least three of these overlap regions of active chromatin in AT (17). Of 296 these signals, only rs7903146 has received attention to date. It has been demonstrated through 297 analysis of GWAS metadata of T2D-related traits (38,39) and human physiological studies (40) that 298 the risk allele at this SNV increases T2D susceptibility via impaired insulin secretion. Additionally, 299 this variant was shown to increase TCF7L2 expression in pancreatic islets (31,41). These data have 300 conclusively established that rs7903146 increases T2D risk primarily through islet dysfunction 301 probably driven by increased TCF7L2 expression in pancreatic beta-cells. Nevertheless, this SNV 302 may also influence T2D predisposition via actions in AT as it was shown to overlap active enhancer 303 histone marks in APs (30) and to be associated with fat distribution (18). Using a "soft clustering" 304 method to group variant-trait associations ascertained from GWAS for 94 independent T2D signals 305 and 47 diabetes-related traits another study also provided some evidence that "lipodystrophy-like" insulin resistance may contribute to T2D predisposition at rs7903146 (39). The same SNV was further 307 shown to overlap a DNA-methylated genomic region exhibiting increased methylation in AT from 308 obese versus lean subjects which was reversed post gastric bypass surgery (32). Extending these 309 findings, we now demonstrate that rs7903146 is an eQTL for TCF7L2 in abdominal APs with the T 310 allele reducing TCF7L2 expression. Whilst the eQTL signal at rs7903146 was only nominally 311 significant our gene expression data were derived from ex vivo expanded APs. This would have added 312 noise to the eQTL dataset in addition to the noise introduced by inter-individual variability in TCF7L2 313 AP expression. We also corroborated our data by demonstrating that the T2D-risk variant at this SNV 314 was associated with reduced AP TCF7L2 protein levels and displayed allele specific enhancer activity 315 in luciferase assays which was directional consistent with the eQTL data. Interestingly rs7903146 316 confers higher T2D susceptibility in lean versus obese subjects (17). Our results offer a possible 317 explanation for this paradox. In our study the T2D-risk variant at this SNV was associated with 318 enhanced age-and BMI-adjusted AT insulin sensitivity which was more pronounced in obese 319 subjects. Whilst we detected no difference in adipocyte size based on rs7903146 genotype, our study 320 sample (n=19) comprised mostly of lean (n=7) and overweight subjects (n=11) due to limited 321 numbers of obese homozygous T2D-risk allele carriers in the Oxford Biobank (see Fig. 6I ). Based 322 on the dose-dependent effects of TCF7L2 on adipogenesis demonstrated herein, it will be interesting 323 to determine whether the T2D-predisposing allele at rs7903146 is associated with differential effects 324 on adipocyte size in lean versus obese subjects; with smaller fat cells specifically seen in obese 325 individuals which have higher baseline AP TCF7L2 expression. 326
327
In summary, our work highlights that TCF7L2 plays an important but complex role in AP biology. 328
We also demonstrate that rs7903146 has cis regulatory effects outside the pancreas and reduces 329 
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